RNA Interference (RNAi) Drug Delivery market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global RNA Interference (RNAi) Drug Delivery market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the RNA Interference (RNAi) Drug Delivery market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Nanoparticle Drug Delivery Technology
Pulmonary Drug Delivery Technology
Nucleic Acid Drug Delivery Technology
Aptamer Drug Delivery Technology
Segment by Application
Infectious Diseases
Cardiology
Oncology
Neurology
Ophthalmology
Metabolic Disorders
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Metabolic disorders
Alnylam Pharmaceuticals Inc
Merck & Co. Inc
Access Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Calondo Pharmaceuticals Inc
Marina Biotech Inc
RXi Pharmaceuticals Corp
Quark Pharmaceuticals Inc
Silence Therapeutics plc
Tacere Therapeutics Inc
PhaseRx Inc
Sirnaomics Inc
Traversa Therapeutics Inc